Resverlogix: The Future of Drug Development

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-bas …

October 4, 2021
Request Investor InfoRequest Investor Info
Resverlogix

Developing safe, epigenetic therapeutics for people suffering from chronic illnesses

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.

For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.

Investing
stock market

You might also like

\Michael Gentile: Why Should Investors Take a Portfolio Approach to Junior Mining?
Other
July 9, 2026

\Michael Gentile: Why Should Investors Take a Portfolio Approach to Junior Mining?

This is some text inside of a div block.
U.S. Gold Corp.: Positioned at the Intersection of Gold and Copper
Metals & Mining
July 7, 2026

U.S. Gold Corp.: Positioned at the Intersection of Gold and Copper

This is some text inside of a div block.
BTV Spotlights: NevGold, Calian Group, Talisker Resources, Dakota Gold, Oreterra Metals, Titan Mining, Nevada Organic Phosphate, Osisko Development
BTV
July 6, 2026

BTV Spotlights: NevGold, Calian Group, Talisker Resources, Dakota Gold, Oreterra Metals, Titan Mining, Nevada Organic Phosphate, Osisko Development

This is some text inside of a div block.
Subscribe and receive the investor Info